Chimerix, Inc. (NASDAQ:CMRX) Files An 8-K Other Events

Chimerix, Inc. (NASDAQ:CMRX) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On June 7, 2018, in the press release attached hereto as Exhibit 99.1, Chimerix, Inc. announced that it was notified by the U.S. Food and Drug Administration that brincidofovir has been granted orphan drug designation for the treatment of patients with smallpox infection.

Forward-Looking Statements

Statements incorporated by reference into this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in our filings with the Securities and Exchange Commission, including without limitation our most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements incorporated by reference into this Current Report on Form 8-K speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


CHIMERIX INC Exhibit
EX-99.1 2 tv496051_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1     Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox   DURHAM,…
To view the full exhibit click here

About Chimerix, Inc. (NASDAQ:CMRX)

Chimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus.

An ad to help with our costs